Affiliation:
1. Alexion Pharmaceuticals, Inc., Cheshire, CT
Abstract
Key PointsThis exploratory study describes the effect of eculizumab on multiple physiologic pathways affected by complement dysregulation in aHUS. The results highlight the importance of sustained terminal complement blockade, even in patients with improved clinical laboratory values.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Cited by
160 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献